Editor - Xianglin L Du | University of Texas Health Science Cent | 4715
ISSN: 2161-1165

Epidemiology: Open Access
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Xianglin L Du

Xianglin L Du
Xianglin L. Du
Division of Epidemiology & Disease Control
University of Texas Health Science Center at Houston
Tel: 713-500-9956
Fax: 713-500-9264


Dr. Xianglin L. Du is an Associate Professor of Epidemiology with tenure at the University of Texas School of Public Health in Houston. He completed his medical degree and his M.S. in clinical epidemiology both at the Anhui Medical University in China, and his Ph.D. in epidemiology and public health at the University of Manchester, England. He has extensive experience in teaching and research in epidemiology, cancer health service and outcomes research in China, England and the United States. He frequently served for the federal grant reviews and study sections, and for the peer-reviewed journal editorial boards. Dr. Du is currently PI of an AHRQ (Agency for Healthcare Research and Quality) funded R01 grant project and is also co-investigator/collaborator for six other grant projects on cancer and women’s health. He has published 88 peer-reviewed articles, many of which are in high impact and top journals in the field.

Research Interest

Clinical Epidemiology, Epidemiology of Cardiovascular Diseases, Epidemiology of Cancer, Health Services Research, Outcomes Research, Breast Cancer Outcomes Research, Nationwide Medicare Claims-Based Research, Disease Registries (cancer and stroke), Patterns of Care Studies, Evaluating the Effectiveness of Health Services and Therapies, Comparative Effectiveness Research on Health Services/Therapies, Disparities in Healthcare and Outcomes, Postmarketing Drug Surveillance of Adverse-Effects or Toxicities.




Enhance the FDA's Postmarketing Drug Surveillance System of Adverse Effects through the Electronic Healthcare Data

Xianglin L Du
Editorial: Epidemiol 2012, 2:e104
DOI: 10.4172/2161-1165.1000e104